Papillomavirus

Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, June 14, 2021
Medicine, Health, Vaccines, Medical research, Vaccitech, Infectious causes of cancer, Papillomavirus, Human papillomavirus infection

OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021, and provided an overview of the Companys recent corporate developments.

Key Points: 
  • OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021, and provided an overview of the Companys recent corporate developments.
  • The first quarter of 2021 was transformational for Vaccitech as we closed a Series B financing round and initiated patient dosing in our two lead therapeutic programs, HBV and HPV, said Bill Enright, CEO of Vaccitech.
  • Subsequent to the end of the first quarter, the Company closed an initial public offering that raised a gross amount of $110.5 million.
  • Research and development (R&D) expenses: Research and development expenses were $4.6 million for the first quarter of 2021 compared to $4.2 million for the comparable period of the prior year.

PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting

Retrieved on: 
Tuesday, June 8, 2021
Cancer, Clinical medicine, Medicine, Papillomavirus, Infectious causes of cancer, Human female reproductive system, Mammal female reproductive system, Gynaecological cancer, Human papillomavirus infection, Vulvar cancer, Immunotherapy, Vagina

An additional four (4) HPV16-positive patients who are checkpoint inhibitor refractory whose data became available after the abstract submission.

Key Points: 
  • An additional four (4) HPV16-positive patients who are checkpoint inhibitor refractory whose data became available after the abstract submission.
  • Most types of HPV-related cancers (anal, cervical, head and neck, vaginal and vulvar cancers) were represented among the study subjects.
  • The company is hosting a conference call tomorrow morning at 8:00 am ET to discuss the data presented at ASCO.
  • The companys lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers.

SQZ Biotechnologies Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors

Retrieved on: 
Friday, June 4, 2021
Research, Infectious diseases, Clinical trials, Other Health, Biotechnology, General Health, Health, Science, Oncology, Other Science, Cancer, Clinical medicine, Carcinogenesis, Carcinogens, Human papillomavirus infection, Papillomavirus, Human Papillomavirus Positive Cancers, SQZ Biotechnologies, HUMAN PAPILLOMAVIRUS POSITIVE CANCERS, SQZ BIOTECHNOLOGIES

The trial also showed that the companys clinical stage manufacturing process of its autologous cell therapy is fast and reliable.

Key Points: 
  • The trial also showed that the companys clinical stage manufacturing process of its autologous cell therapy is fast and reliable.
  • Within this small trial of patients with very advanced disease, four patients who had progressed after multiple prior therapies achieved stable disease.
  • Findings from the trial show that SQZ-PBMC-HPV was safe and well-tolerated at all tested dose levels with patients receiving 2 to 10 doses.
  • The 12 enrolled patients had very advanced disease:
    Six of the 12 patients had a Royal Marsden Hospital (RMH) score of 2.

Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated SafeSEQ NGS HPV16/18 liquid biopsy assay, is highly effective for measuring HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OP

Retrieved on: 
Wednesday, June 2, 2021
Clinical medicine, Medicine, Cancer, Infectious causes of cancer, Papillomavirus, Polymerase chain reaction, Cancer screening, Biopsy, Liquid biopsy, Digital polymerase chain reaction, Human papillomavirus infection

The ASCO presentation coincides with the launch of HPV-SEQ as the newest CLIA validated assay in the Sysmex Inostics portfolio of ultra-sensitive SafeSEQ NGS panels.

Key Points: 
  • The ASCO presentation coincides with the launch of HPV-SEQ as the newest CLIA validated assay in the Sysmex Inostics portfolio of ultra-sensitive SafeSEQ NGS panels.
  • Sysmex Inostics has introduced HPV-SEQ, an ultra-sensitive blood-based liquid biopsy solution for identifying and accurately quantifying circulating HPV 16 and HPV 18 DNA in patients with HPV-related cancers.
  • Importantly, a high correlation was observed between dynamic changes in patients' cfHPV DNA levels and radiographic responses following induction therapy.
  • Sysmex Inostics, a Sysmex Corporation subsidiary, empowers discoveries in oncology by providing investigators cost-effective and ultra-sensitive quantitative liquid biopsy solutions, OncoBEAM (digital PCR) and SafeSEQ (NGS).

Naveris' New Saliva Test Detects Head and Neck Cancer

Retrieved on: 
Wednesday, June 2, 2021
Oncology, Health, Clinical trials, Research, Science, Biotechnology, Cancer, Clinical medicine, Infectious causes of cancer, Medicine, Papillomavirus, Otorhinolaryngology, Gynaecological cancer, Health effects of tobacco, Human papillomavirus infection, Head and neck cancer, Squamous cell carcinoma, Saliva testing, Oropharyngeal Cancer, Naveris, Inc., OROPHARYNGEAL CANCER, NAVERIS, INC.

A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result.

Key Points: 
  • A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result.
  • The study results point to the potential for a significant improvement in early detection of the most common type of head and neck cancer, HPV-associated oropharyngeal squamous cell carcinoma.
  • Naveris patient-friendly saliva test has the potential to radically advance early detection of HPV-positive head and neck cancer, which has been growing rapidly among men in the United States.
  • NavDx is a liquid biopsy test that detects HPV-associated head and neck cancer earlier than is possible with imaging and is provided exclusively in the United States through the Naveris national reference CAP-accredited laboratory.

PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance

Retrieved on: 
Thursday, May 27, 2021
Cancer, Clinical medicine, Medicine, Infectious causes of cancer, Papillomavirus, Otorhinolaryngology, Health effects of tobacco, Sexually transmitted diseases and infections, Human papillomavirus infection, Head and neck cancer, Immunotherapy, Head and Neck Cancer Alliance

FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Companys proprietary Versamune T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership.

Key Points: 
  • FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Companys proprietary Versamune T-cell activating technology, and the Head and Neck Cancer Alliance (HNCA) today announced a partnership.
  • Because head and neck cancer is often diagnosed at later stages, treatment is often more difficult and more invasive.
  • There are exciting things happening in clinical research for head and neck cancer therapies, said Amanda Hollinger, Executive Director of HNCA.
  • In 2018, head and neck cancer surpassed cervical cancer as the most common HPV-attributed cancer in the United States.

PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting

Retrieved on: 
Monday, May 24, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Carcinogenesis, Carcinogens, Human papillomavirus infection, National Cancer Institute

During the call, PSD Biotech will review data from the previously announced oral presentation from the National Cancer Institute (NCI)-led phase 2 trial of PDS0101 in triple combination for the treatment of advanced HPV-associated cancers.

Key Points: 
  • During the call, PSD Biotech will review data from the previously announced oral presentation from the National Cancer Institute (NCI)-led phase 2 trial of PDS0101 in triple combination for the treatment of advanced HPV-associated cancers.
  • Following the presentation, PDS Biotech will hold a question-and-answer session.
  • The conference call is scheduled to begin at 8:00 am ET on Tuesday, June 8, 2021.
  • A copy of PDS Biotech's presentation will be available on June 8th on the scientific presentations and publications page of PDS Biotech's website.

Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing

Retrieved on: 
Monday, May 24, 2021
Cancer, Medical specialties, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Vaccination, Papillomavirus, Human papillomavirus infection, Cervical cancer, Ovarian cancer, Vaccine, Bradley Monk

His clinical background and research interests match those of BioVaxys and include ovarian cancer, cervical cancer, and human papillomavirus ("HPV").

Key Points: 
  • His clinical background and research interests match those of BioVaxys and include ovarian cancer, cervical cancer, and human papillomavirus ("HPV").
  • "I am very excited to join Biovaxys as an advisor for both the ovarian cancer vaccine and the treatment of cervical HPV" said Dr. Dunton.
  • "Ovarian cancer remains a deadly disease and the need for a novel treatment such as a vaccine is important."
  • The Company is developing BVX-0320, its SARS-CoV-2 vaccine candidate, and is advancing a clinical study of BVX-0918A, its cancer vaccine in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors, in late-stage ovarian cancer.

Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing

Retrieved on: 
Monday, May 24, 2021
Cancer, Medical specialties, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Vaccination, Papillomavirus, Human papillomavirus infection, Cervical cancer, Ovarian cancer, Vaccine, Bradley Monk

His clinical background and research interests match those of BioVaxys and include ovarian cancer, cervical cancer, and human papillomavirus ("HPV").

Key Points: 
  • His clinical background and research interests match those of BioVaxys and include ovarian cancer, cervical cancer, and human papillomavirus ("HPV").
  • "I am very excited to join Biovaxys as an advisor for both the ovarian cancer vaccine and the treatment of cervical HPV" said Dr. Dunton.
  • "Ovarian cancer remains a deadly disease and the need for a novel treatment such as a vaccine is important."
  • The Company is developing BVX-0320, its SARS-CoV-2 vaccine candidate, and is advancing a clinical study of BVX-0918A, its cancer vaccine in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors, in late-stage ovarian cancer.

Perlmutter Cancer Center at NYU Langone Health Joins Call For Urgent Action To Get Cancer-Preventing HPV Vaccination Back On Track

Retrieved on: 
Friday, May 21, 2021
Cancer, Clinical medicine, Papillomavirus, Vaccination, Infectious causes of cancer, Cancer vaccines, Vaccines, Gynaecological cancer, HPV vaccine, Human papillomavirus infection, Vaccine, Gardasil

Despite those staggering figures and the availability of a vaccine to prevent HPV infections, HPV vaccination rates remain significantly lower than other recommended adolescent vaccines in the U.S.

Key Points: 
  • Despite those staggering figures and the availability of a vaccine to prevent HPV infections, HPV vaccination rates remain significantly lower than other recommended adolescent vaccines in the U.S.
  • Even before the COVID-19 pandemic, HPV vaccination rates lagged far behind other vaccines and other countries\' HPV vaccination rates.
  • Catch-up HPV vaccination is recommended through age 26.\nNCI Cancer Centers strongly encourage parents to vaccinate their adolescents as soon as possible.
  • "\nMore information on HPV is available from the CDC and National HPV Vaccination Roundtable .